Clinical Trials Logo
  1. Home
  2. Advanced Malignant Solid Tumor
  3. NCT04275050

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets

Advanced Malignant Solid Tumor Clinical Trial

Official title:
A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets

Clinical Trial Summary

TQB3303 tablet is a small molecule oral drug inhibiting cyclin-dependent kinases 4 and 6 (CDK4 / 6). Based on current research, overexpression of positive regulatory proteins in the cell cycle is one of the important reasons for resistance to endocrine therapy. CDK4 / 6 is the key regulators of the cell cycle inhibiting tumor cell proliferation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04275050
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Binghe Xu, doctor
Phone 010-87788826
Email xubinghe@medmail.com.cn
Status Not yet recruiting
Phase Phase 1
Start date April 2020
Completion date April 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04864379 - Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors Phase 1
Recruiting NCT04165590 - Plasmodium Immunotherapy for Advanced Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT05098405 - First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors Phase 1
Recruiting NCT06150183 - Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT05911984 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05396339 - A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors. Phase 1/Phase 2
Recruiting NCT03171220 - Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors Phase 1/Phase 2
Recruiting NCT04241835 - A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function Phase 1
Active, not recruiting NCT03662815 - Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor Phase 1
Not yet recruiting NCT06166472 - A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor Phase 1
Recruiting NCT05477849 - A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients With Solid Tumors Phase 1
Recruiting NCT04758897 - Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors Phase 1